BioCryst
Medical AFFAIRS
Navigate the Biocryst Medical Affairs Hub with ease
Throughout this resource hub you will find up-to-date information on developing and approved BioCryst medicines, including clinical trials, congress information, published data, and other research material.
Search for medical information
Find information on BioCryst products.
Find information
on upcoming and previous congresses
Upcoming Congress Events
Western Society of Allergy, Asthma and Immunology (WSAAI)
BioCryst will attend the 2026 Western Society of Allergy, Asthma and Immunology (WSAAI) from Feb 1-5, 2026.
Visit the Congress Website for More Information
Materials From Recent Congresses
Showing 122 Materials
-
Oral Berotralstat Reduces Hereditary Angioedema Attack Rates in Pediatric Patients Aged 2 to <12 Years Without Long-Term Prophylaxis During the 12-Week Standard of Care Period: Interim Data from the APeX-P Study
WSAAI | 2026 | HAE -
Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)
HAEi EMEA | 2025 | HAE -
Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
HAEA National Summit | 2025 | HAE -
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
HAEA National Summit | 2025 | HAE -
ALPHA-ORBIT -A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)
HAEA National Summit | 2025 | HAE
Current clinical trials and research
Learn more about medicines being developed at BioCryst and see the latest studies.
Discover more about our areas of focus
See our video library
Learn more about research within our areas of focus.
Ready to connect or have a question?
Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?
Have questions about our company?